ATM and metastatic prostate carcinoma: Pritchard et al. reported that germline pathogenic variants in DNA-repair genes were more frequent in men with metastatic prostate cancer than in men with localized disease (82/692, 11.8% and 23/499, 4.6%, respectively; p < 0.001), with the highest number of pathogenic variants being identified in BRCA2 (5.3%), ATM (1.6%), and CHEK2 (1.9%) in men with metastatic disease [13].